Alzheimer's Diagnostic Lab to Triple Capacity by 2027
The St. Louis facility expansion aims to scale clinical testing capacity for patients.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Do specialized innovation districts successfully keep growing companies within your local community?
St. Louis-based C2N Diagnostics is set to triple its operational footprint by moving into a new 82,451-square-foot facility at the Catalyst building. The expansion, scheduled for 2027, will significantly increase clinical testing capacity for Alzheimer’s disease markers.
Why it matters
As demand for diagnostic Alzheimer's testing grows, the need for specialized laboratory infrastructure increases to support sophisticated biomarker analysis. This facility move aims to accommodate that rising clinical volume while leveraging the research environment of the Cortex Innovation District.
C2N Diagnostics has secured an 82,451-square-foot expansion across three floors at the Catalyst building, providing three to four times their current clinical laboratory space. The exact increase in diagnostic test throughput remains to be determined.
The players
C2N Diagnostics
A clinical laboratory company that specializes in diagnostic testing for Alzheimer's disease using mass spectrometry.
Cortex Innovation District
A research and technology hub in St. Louis that hosts the Catalyst building.
The details
The facility will be equipped with specialized infrastructure to support liquid chromatography-tandem mass spectrometry, the primary method used to measure biological markers for Alzheimer's. By partnering with architects and engineers, the company is designing custom laboratory environments optimized for this high-precision instrumentation. This infrastructure is essential for the complex processing required to identify Alzheimer's-related proteins in clinical samples.
Timeline
September 2025: C2N Diagnostics announced plans to move into the Catalyst building.
2027: The company expects to begin scaling up clinical testing operations at the new site.
Health Landscape
This facility expansion reflects the broader growth of precision diagnostics within the St. Louis biotech corridor. It follows the pattern of established firms scaling infrastructure to keep pace with the evolving field of Alzheimer's biomarker testing.
For patients undergoing Alzheimer's screening, this expansion signals an increase in local capacity for sophisticated biomarker testing. If you are discussing diagnostic options with your doctor, ask how these clinical testing capabilities may impact the timing and availability of results.
The takeaway
As clinical testing for Alzheimer's markers becomes more common, laboratory capacity is expanding to meet the need for precise diagnostic data. Patients should continue to discuss the clinical utility of these biomarkers and appropriate screening protocols with their primary care physician.
Further reading
Learn more about the latest developments in clinical research at our Alzheimer’s section.
Source note: This article includes information reported by St. Louis Magazine.
Live Poll
Do specialized innovation districts successfully keep growing companies within your local community?
